Patricia Guyot

3.3k total citations · 1 hit paper
43 papers, 2.2k citations indexed

About

Patricia Guyot is a scholar working on Oncology, Hematology and Rheumatology. According to data from OpenAlex, Patricia Guyot has authored 43 papers receiving a total of 2.2k indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Oncology, 10 papers in Hematology and 9 papers in Rheumatology. Recurrent topics in Patricia Guyot's work include Health Systems, Economic Evaluations, Quality of Life (5 papers), Hemophilia Treatment and Research (5 papers) and Diabetes Management and Research (4 papers). Patricia Guyot is often cited by papers focused on Health Systems, Economic Evaluations, Quality of Life (5 papers), Hemophilia Treatment and Research (5 papers) and Diabetes Management and Research (4 papers). Patricia Guyot collaborates with scholars based in France, United States and United Kingdom. Patricia Guyot's co-authors include A. E. Ades, Nicky J. Welton, Shaloo Pandhi, Richard M. Nixon, R Andrew Moore, Andreas Karabis, Yingxin Xu, Jean‐Pierre Pignon, B. Lueza and Jérôme Msihid and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Annals of the Rheumatic Diseases.

In The Last Decade

Patricia Guyot

42 papers receiving 2.2k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Enhanced secondary analysis of survival data: reconstructing the data from published Kaplan-Meier survival curves

2012 1.7k citations Patricia Guyot, A. E. Ades et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Patricia Guyot France	12	757	698	430	305	261	43	2.2k
Paul Blanche Denmark	17	320 0.4×	566 0.8×	234 0.5×	82 0.3×	444 1.7×	63	2.0k
Nadine Houédé France	26	767 1.0×	733 1.1×	908 2.1×	115 0.4×	484 1.9×	136	2.5k
Susanna Jacobus United States	24	1.2k 1.6×	431 0.6×	404 0.9×	117 0.4×	1.3k 5.1×	59	2.8k
Denise K. Reinke United States	22	1.2k 1.5×	1.7k 2.4×	231 0.5×	155 0.5×	346 1.3×	54	2.8k
Kevin Knopf United States	20	772 1.0×	494 0.7×	266 0.6×	285 0.9×	131 0.5×	73	1.7k
Ralph M. Meyer Canada	36	1.7k 2.3×	827 1.2×	606 1.4×	153 0.5×	449 1.7×	139	4.7k
Ker‐Ai Lee Canada	22	973 1.3×	550 0.8×	248 0.6×	49 0.2×	219 0.8×	54	2.4k
Sidney Scudder United States	20	603 0.8×	316 0.5×	281 0.7×	246 0.8×	406 1.6×	49	1.9k
Michael Tanaka United States	13	582 0.8×	767 1.1×	576 1.3×	245 0.8×	173 0.7×	21	1.9k
Ali McBride United States	28	1.4k 1.8×	516 0.7×	148 0.3×	343 1.1×	490 1.9×	234	2.7k

Countries citing papers authored by Patricia Guyot

Since Specialization

Citations

This map shows the geographic impact of Patricia Guyot's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Patricia Guyot with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Patricia Guyot more than expected).

Fields of papers citing papers by Patricia Guyot

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Patricia Guyot. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Patricia Guyot. The network helps show where Patricia Guyot may publish in the future.

Co-authorship network of co-authors of Patricia Guyot

This figure shows the co-authorship network connecting the top 25 collaborators of Patricia Guyot. A scholar is included among the top collaborators of Patricia Guyot based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Patricia Guyot. Patricia Guyot is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Ständer, Sonja, Andreas Pinter, Patricia Guyot, et al.. (2025). Dupilumab versus Lebrikizumab Demonstrates Greater Likelihood of Achieving and Maintaining Improvements in Efficacy Outcomes Using a Placebo-Adjusted Indirect Treatment Comparison. Dermatology and Therapy. 15(9). 2537–2551. 1 indexed citations

Roberts, Mark, Irina Proskorovsky, Patricia Guyot, et al.. (2025). An Indirect Treatment Comparison of Avalglucosidase Alfa versus Cipaglucosidase Alfa Plus Miglustat in Patients with Late-Onset Pompe Disease. Advances in Therapy. 42(11). 5578–5599.

Román, María, et al.. (2024). Efanesoctocog Alfa Versus Emicizumab in Adolescent and Adult Patients With Haemophilia A Without Inhibitors. Advances in Therapy. 42(1). 442–455. 1 indexed citations

Guyot, Patricia, et al.. (2024). Efanesoctocog Alfa versus Standard and Extended Half-Life Factor VIII Prophylaxis in Adolescent and Adult Patients with Haemophilia A without Inhibitors. Advances in Therapy. 42(1). 427–441. 1 indexed citations

Hopkins, Claire, Joseph K. Han, Wytske J. Fokkens, et al.. (2024). Dupilumab Versus Mepolizumab for Chronic Rhinosinusitis With Nasal Polyposis: An Indirect Treatment Comparison. The Journal of Allergy and Clinical Immunology In Practice. 12(12). 3393–3401.e15. 11 indexed citations

Bullement, Ash, Patricia Guyot, Nicky J. Welton, et al.. (2024). MPES-R: Multi-Parameter Evidence Synthesis in R for Survival Extrapolation—A Tutorial. PharmacoEconomics. 42(12). 1317–1327. 1 indexed citations

Feliciano, Josephine, Yingxin Xu, Ruben G.W. Quek, et al.. (2023). Impact of the treatment crossover design on comparative efficacy in EMPOWER-Lung 1: Cemiplimab monotherapy as first-line treatment of advanced non-small cell lung cancer. Frontiers in Oncology. 12. 1081729–1081729. 5 indexed citations

Roberts, Mark, Irina Proskorovsky, Patricia Guyot, et al.. (2023). CO122 Late-Onset Pompe Disease (LOPD) Patients Treated with Avalglucosidase Alfa Show Favorable Results Compared to Cipaglucosidase Alfa Plus Miglustat: Indirect Treatment Comparison. Value in Health. 26(6). S37–S38. 1 indexed citations

Ritzel, Robert, Sujoy Ghosh, Rıfat Emral, et al.. (2023). Comparative efficacy and safety of Gla‐300 versus IDegAsp in insulin‐naïve people with type 2 diabetes mellitus uncontrolled on oral anti‐diabetics. Diabetes Obesity and Metabolism. 25(9). 2495–2504. 3 indexed citations

10.

Klamroth, Robert, Patricia Guyot, A. Arnaud, et al.. (2023). PB0201 Efanesoctocog Alfa Versus Extended Half-Life Factor VIII Therapies for Prophylaxis in Adolescents and Adults with Severe Hemophilia A: A Matching-Adjusted Indirect Comparison and Meta-Analysis. Research and Practice in Thrombosis and Haemostasis. 7. 101290–101290. 1 indexed citations

11.

Román, María, Nana Kragh, Patricia Guyot, et al.. (2023). PB0195 Efanesoctocog Alfa Versus Emicizumab in the Prophylactic Treatment of Adolescents and Adults with Severe Hemophilia A without Inhibitors: A Matching-Adjusted Indirect Comparison. Research and Practice in Thrombosis and Haemostasis. 7. 101295–101295. 1 indexed citations

12.

Leleu, Xavier, et al.. (2022). POSC34 Comparative Efficacy and Safety of Isatuximab Plus Pomalidomide and Dexamethasone Versus Daratumumab Plus Pomalidomide and Dexamethasone in Patients with Multiple Myeloma Using a Matching-Adjusted Indirect Comparison. Value in Health. 25(1). S39–S39. 2 indexed citations

13.

Freemantle, Nick, Yingxin Xu, Patricia Guyot, et al.. (2022). Network meta-analysis of immune-oncology monotherapy as first-line treatment for advanced non-small-cell lung cancer in patients with PD-L1 expression ⩾50%. Therapeutic Advances in Medical Oncology. 14. 4287517056–4287517056. 1 indexed citations

14.

Rayner, Christopher K., Tongzhi Wu, Vanita R. Aroda, et al.. (2020). Gastrointestinal adverse events with insulin glargine/lixisenatide fixed‐ratio combination versus glucagon‐like peptide‐1 receptor agonist s in people with type 2 diabetes mellitus: A network meta‐analysis. Diabetes Obesity and Metabolism. 23(1). 136–146. 16 indexed citations

15.

Home, Philip, Lawrence Blonde, Sanjay Kalra, et al.. (2020). Insulin glargine/lixisenatide fixed‐ratio combination ( iGlarLixi ) compared with premix or addition of meal‐time insulin to basal insulin in people with type 2 diabetes: A systematic review and Bayesian network meta‐analysis. Diabetes Obesity and Metabolism. 22(11). 2179–2188. 16 indexed citations

16.

Home, Philip, Vanita R. Aroda, Lawrence Blonde, et al.. (2020). Efficacy and safety of iGlarLixi versus IDegLira in adults with type 2 diabetes inadequately controlled by glucagon‐like peptide‐1 receptor agonists: a systematic literature review and indirect treatment comparison. Diabetes Obesity and Metabolism. 22(11). 2170–2178. 11 indexed citations

17.

Guyot, Patricia, et al.. (2017). Efficacy and safety of diclofenac in osteoarthritis: Results of a network meta-analysis of unpublished legacy studies. Scandinavian Journal of Pain. 16(1). 74–88. 9 indexed citations

18.

Guyot, Patricia, Nicky J. Welton, Mary Beth Beasley, & A. E. Ades. (2014). Extrapolation of Trial-Based Survival Curves Using External Information. Value in Health. 17(7). A326–A326. 5 indexed citations

19.

Guyot, Patricia, Peter C. Taylor, Robin Christensen, et al.. (2011). Abatacept with methotrexate versus other biologic agents in treatment of patients with active rheumatoid arthritis despite methotrexate: a network meta-analysis. Arthritis Research & Therapy. 13(6). R204–R204. 38 indexed citations

20.

Guyot, Patricia, Nicky J. Welton, Mario Ouwens, & A. E. Ades. (2011). Survival Time Outcomes in Randomized, Controlled Trials and Meta-Analyses: The Parallel Universes of Efficacy and Cost-Effectiveness. Value in Health. 14(5). 640–646. 31 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact